illness, 6 and (3) the age dependence of genetic as well as sporadic forms-the annual peak incidence is 3-6 cases per million people between 65 and 79 years of age. 6, 7 Despite their rarity, human prion diseases have gained considerable importance because their unique etiology and pathogenesis challenged basic principles of biology. Furthermore, prion diseases can be transmitted between humans as well as from animals to humans by an agent that is highly resistant to inactivation and which thus poses novel problems to disease control and public health. Finally, because of the marked heterogeneity of their clinical phenotype, prion diseases are difficult to differentiate from other age-related brain neurodegenerations, a feature that has prompted the establishment of specialized prion disease surveillance centers worldwide. Human prion diseases also include inherited forms as well as forms acquired by infection (Table 1) . However, this review focuses on the molecular aspects of the pathogenesis of sporadic forms.
Mini-Review
Mini-Review to which the infectious pathogen responsible for human prion diseases is an abnormal protein, designated PrP Sc . 1 The discovery that proteins could be infectious represented a new paradigm of molecular biology and medicine. Although originally deemed heretical, this protein-only model is now supported by a wealth of biochemical, genetic and animal studies. 6, [35] [36] [37] [38] Moreover, the concept of prion diseases has important implications for other neurodegenerative disorders. Recent studies with amyloid β, tau, α-synuclein, huntingtin and superoxide dismutase 1 suggest that molecular and cellular mechanims that were first discovered in studies of prions are involved in the pathogenesis of other neurodegenerative disorders associated with the accumulation of misfolded proteins, including Parkinsonism, Huntington disease, amyotrophic lateral sclerosis (ALS) and Alzheimer disease. [39] [40] [41] [42] [43] 
Pathogenetic Mechanisms of Human Sporadic Prion Diseases
The basic event shared by all three forms of prion diseases-sporadic, inherited and acquired by infection-is a change in conformation of the normal or cellular PrP (PrP C ) which is converted into a pathogenic PrP isoform commonly identified as PrP Sc for prototypic scrapie (Sc) PrP. 1 Human PrP C is encoded by the PrP gene (PRNP) on chromosome 20 and expressed at different levels in most mammalian cells. It comprises 209 amino acids (23-231), two sites of N-linked glycosylation, a disulfide bond and a glycolipid anchor. [44] [45] [46] [47] [48] [49] The variable degree of glycosylation is responsible for the presence of di-, mono-and un-glycosylated forms of PrP C . Because of the glycolipid anchor, most of the PrP C is extracellularly linked in specialized cholesterol-rich domains (caveoli) of the cell plasma membrane. 48, 50 In normal conformation, human PrP C comprises a C-terminal globular domain (involving residues 127-231), which consists of three α-helices and two short β-sheets. 51 In contrast, the N-terminus is unstructured. 51 The PrP Sc , in contrast, is pathogenic, infectious and displays different biophysical features, forming insoluble aggregates of different sizes with predominantly β-sheet secondary structure; the C-terminal region is relatively resistant to proteolytic degradation. [52] [53] [54] The conformational transition that underlies these pronounced changes is believed to involve refolding of the features of sporadic CJD.
14 Subsequently, new sporadic forms of the spongiform encephalopathies with unique phenotypic features were described; specifically, sporadic fatal insomnia (SFI) in 1997, 15, 16 and the latest likely new candidate, variable proteasesensitive prionopathy (VPSPr) in 2008. 17 Controversy concerning the cause of human spongiform encephalopathies has polarized the scientific community for decades. The 1950s saw considerable interest in an epidemic of a neurodegenerative disease, kuru, characterized principally by a progressive cerebellar ataxia, among the Fore people of the Eastern Highlands of Papua New Guinea. 18, 19 Fieldwork by Carleton Gajdusek and Vincent Zigas suggested that kuru was transmitted during cannibalistic feasts. 20 Importantly, in 1959 Hadlow pointed out the similarities between kuru and scrapie of sheep at the neuropathologic and clinical levels and suggested that human diseases might also be transmissible. 21 Subsequent transmission of kuru (in 1966) and then CJD (in 1968) by intracerebral inoculation of brain homogenates into chimpanzees, work which was conducted by Gajdusek, Gibbs and colleagues, was a landmark discovery which led to the concept of the "transmissible spongiform encephalopathies." 22, 23 The transmission of Gerstmann-Sträussler-Scheinker disease (GSS) followed in 1981 24 and fatal familial insomnia (FFI) in 1995. 25 Interestingly, Jakob, suspecting in his original observations that the condition might be transmissible, inoculated rabbits experimentally, in an attempt to demonstrate this in the 1920s. 26 However, thanks to the important role of serendipity in science, his experiment was unsuccessful and we know now that rabbits are uniquely resistant to prion infections. 27 The transmission of CJD and of kuru allowed refinement of the diagnostic pathologic criteria for human spongiform encephalopathy and led to the conclusion that all the human conditions share common histopathologic features: spongiform vacuolation (affecting any part of the cerebral gray matter), neuronal loss and astrocytic proliferation that may be accompanied by amyloid plaques. [28] [29] [30] [31] One analogy with scrapie in sheep, it was assumed that the causative agent must be some type of atypical "slow virus," the term Sigurdsson coined in 1954 for scrapie infection. 2, 32 Regrettably, despite extensive efforts in Europe and the US, no non-host DNA or RNA could be found, and a growing body of data pointed to a causative agent having unique characteristics. 33, 34 Most researchers today accept the model according Zoonotic infection with bovine prions variant Creutzfeldt-Jakob disease infection from prion-contaminated human growth hormone, dura mater grafts, etc. iatrogenic Creutzfeldt-Jakob disease laboratory rodent prion strains, in which the digestion of brain PrP Sc with proteolytic enzyme proteinase K (PK) consistently results in a single protease-resistant domain with mass ~19 kDa, the outcome in sCJD is more complex. Distinctive glycosylation patterns and up to four PK-resistant fragments of the pathogenic prion protein (rPrP Sc ) found in sCJD brains are easily distinguishable on western blot (WB). 5, 71, [74] [75] [76] [77] The WB findings together with human PRNP gene polymorphism led Parchi, Gambetti and colleagues to posit a clinicopathological classification of sCJD into five or six subtypes; notably, the WB characteristics of PrP Sc breed true upon transmission to susceptible transgenic mice and Guinea pigs (Cavia porcellus). 5, 71, 74, 78 An alternative classification of the PrP Sc types and their pairing with CJD phenotypes has been proposed by Collinge and collaborators. 37, 75, 76, 79 This classification differs from the previous one in two major aspects: first, it recognizes three (not two) PrP
Sc electrophoretic mobilities and second, it also identifies PrP Sc isoforms with different ratios of the three PrP glycoforms. 37 Although the disease phenotypes of patients with sCJD are remarkably heterogeneous, 21 kDa fragments of unglycosylated PrP Sc (Type 1) frequently differ from the disease duration and phenotypes associated with the 19 kDa fragments of unglycosylated PrP Sc (Type 2). 3, 5, 71, 74 Cumulatively, these findings argue that the PrP Sc type represents yet an additional major modifier of the phenotype in human prion diseases; accordingly, WB-based clinicopathologic classifications became an important tool in studies of prion pathogenesis in human brains and in transgenic mice models. 37, 71 Because two distinct PK cleavage sites in PrP Sc Types 1 and 2 most likely stem from distinct conformations, some investigators contend that PrP Sc Types 1 and 2 code distinct prion strains. 3, 71, 75, 80 However, the heterogeneity of sCJD, along with a growing number of studies including bioassays, all suggest that the range of prions causing sCJD exceeds the number of categories recognized within the current WB-based clinicopathologic schemes. [81] [82] [83] Additionally, recent findings of the co-occurrence of PrP Sc Types 1 and 2 in 40% or more sCJD cases created a conundrum and suggested that the originally observed differences were quantitative rather than qualitative. [84] [85] [86] [87] [88] [89] Finally, up to 90% of brain PrP Sc in sCJD eludes WB analysis because it is destroyed by proteinase-K treatment, which is necessary to eliminate PrP C . 81 Consequently, the conformation or role of this major protease-sensitive (s) fraction of PrP Sc in the pathogenesis of the disease is a subject of speculation. 64, 81, 90 Thus, no direct structural data are available for sCJD brain PrP Sc beyond the evidence that it is resistant to proteolytic digestion. Nevertheless, to determine the full spectrum of sCJD prion strains, and the conformational features in the pathogenic human prion protein governing replication of sCJD prions is fundamental for the rational development of diagnostic as well as therapeutic strategies.
Novel Conformational Methods Derived from a Conformation-dependent Immunoassay (CDI)
Three obstacles have slowed progress in the research of human prions: phenotypic variability of sCJD on complex genetic C-terminal region whereby the α-helical structures of PrP C are replaced by β-sheet to different extents and with variable patterns. 55 Although insolubility and protease resistance were the original defining features of PrP Sc , the finding of protease-sensitive small oligomers of pathogenic PrP Sc 56, 57 significantly broadened the spectrum of pathogenic conformers.
Although some authors believe that the toxicity in prion disease can be explained as a loss of function of PrP C due to the conformational transformation, 58 others argue that a gain of toxic function is more likely. 59, 60 Nevertheless, there is general agreement that PrP C serves as a substrate for conversion to PrP Sc and as a major receptor for toxic effects of PrP Sc . Thus the neuroprotective function physiologically provided by PrP C could be lost following its conversion to PrP Sc . The prevailing presence of PrP Sc on neuronal plasma membrane also at the synapse might explain the widespread spongiform degeneration, which can be viewed as intracellular edema. All these changes are pathognomonic of sCJD. Apoptosis and oxidative stress are reported to occur when PrP Sc aggregates form at the cell surface and may well contribute to the neuronal cell loss that is prominent in prion diseases of long duration and in prion diseases like SFI, which manifest no or minimal spongiosis as well as severe neuronal loss. 61 Astrogliosis, a common reaction to injury, is considered a secondary response.
The Origin and Phenotypic Heterogeneity of sCJD
Several explanations have been proposed for the etiology of sporadic prion diseases. These include spontaneous somatic mutations in the PRNP gene or rare stochastic conformational changes in the structure of PrP C . 62 These explanations presuppose that the mutant PrP
Sc would have to be capable of recruiting wild-type PrP C ; however, this process which might occur with some mutations or conformations but is unlikely with others. 63 According to a second explanation, low amounts of PrP Sc -like isoforms are normally present in brain, and possibly bound to other proteins such as heat shock proteins, however, this protective mechanism fails with aging. 64, 65 Finally, it has been suggested that at least some cases of apparent sCJD result from covert, low-level exposure to a "common external factor." 66 With more cases investigated after the original reports by Jakob, it became clear that the clinical as well as histopathologic features of sCJD are remarkably diverse, perhaps making the human prion diseases the most heterogeneous of all neurodegenerative disease. On the basis of predominant clinical and pathologic features, the following phenotypic subtypes of sCJD were proposed in the 1980s: (1) myoclonic or cortico-striatalspinal, (2) amaurotic or Heidenhain, (3) classical or diffuse, (4) thalamic, (5) ataxic or cerebellar and (6) amyotrophic. [67] [68] [69] Researchers today generally agree that the genotype at codon 129 of the chromosomal gene PRNP, and to some degree the phenotypes of these diseases, underlie susceptibility to prion diseases. 5 Additionally, many lines of evidence from experiments with laboratory prion strains support the view that the phenotype of sCJD-its distinctive incubation time, clinical features and brain pathology-is enciphered in the strain-specific conformation of PrP Sc . 56, [70] [71] [72] [73] Our recent finding of 6-fold difference in concentrations of PrP Sc between Type 1 and Type 2 PrP Sc (129M) in the frontal cortex was surprising, even though some variability was to be expected due to differences in the predominantly affected areas in distinct sCJD phenotypes. 81, 92 Moreover, the average levels of PrP Sc were up to 100-fold lower than those in standard laboratory prion models such as Syrian hamsters infected with Sc237 prions; 56 and together with the up to 100-fold variability within each phenotypic group, these lower levels of PrP Sc may explain why some sCJD cases are difficult to transmit, and why lower endpoint titers are obtained with human prions in transgenic mice expressing human or chimeric PrP C . 37, 71, 81, 103 Up to 90% of the pathogenic prion protein in sCJD is protease-sensitive 81 and we found the highest concentrations in Type 2 PrP Sc (129M) (Fig. 1) . 92 The broad range of absolute and relative levels of rPrP Sc and sPrP Sc offers evidence of a broad spectrum of PrP Sc molecules differing in protease sensitivity in each group with an identical polymorphism at codon 129 of the PRNP gene and an identical WB pattern. Moreover, these findings signal the existence of a variety of sCJD PrP Sc conformers; and since protease sensitivity is one of the characteristics of prion strains, they also suggest that distinct sCJD prion strains exist. 56, 57, 81, 82, 104, 105 The heterogeneity of PrP Sc conformations we found with CDI within sCJD patients homozygous for codon 129 plymorphism of the PRNP gene is remarkable, having a range corresponding to that of stabilities found in approximately 30 distinct strains of de-novo and natural laboratory rodent prions studied up to now. 56, 72, 92, 106 The intriguing differential effect of PK treatment background, biosafety constraints, and lack of suitable tools for studying molecular characteristics beyond WB typing. Aiming to advance our understanding of the molecular pathogenesis of human prion diseases, we developed the conformation-dependent immunoassay (CDI), 56, 81, 91 to determine the conformational range and strain-dependent molecular features of sCJD PrP Sc , first in patients who were homozygous for codon 129 of the PRNP gene. 92 Even relatively minute variations in a soluble protein structure can be determined by measuring conformational stability in a denaturant such as Gdn HCl. 93 Utilizing this concept, we designed a procedure in which PrP Sc is first exposed to denaturant Gdn HCl and then exposed to europium-labeled mAb against the epitopes hidden in the native conformation. 56 As the concentration of Gdn HCl increases, PrP Sc dissociates and unfolds from native β-sheet-structured aggregates, and more epitopes become available to antibody binding. These experiments involve insoluble oligomeric forms of PrP Sc , and denaturation of this protein is irreversible in vitro; consequently the Gibbs free energy change (ΔG) of PrP
Sc cannot be calculated. 94 Therefore we chose instead to use the Gdn HCl value found at the half-maximal denaturation ([GdnHCl] 1/2 ) as a measure of the relative conformational stability of PrP Sc . The differences in stability reveal evidence of distinct conformations of PrP Sc . 56, 93, 94 To measure the concentration of different forms of PrP Sc and follow the unfolding, we used europium-labeled mAb 3F4 95 (epitope residues 107-112) for detection and 8H4 mAb (epitope residues 175-185), 96 to capture human PrP Sc in a sandwich CDI format. 81, 97 The analytical sensitivity and specificity of the optimized CDI for detection of PrP Sc was previously reported by us and others in numerous publications 56, 81, 91, [98] [99] [100] and has been shown to be as low as ~500 fg (~20 attomoles) of PrP Sc which is similar to the sensitivity of human prion bioassay in Tg(MHu2M)5378/Prnp 0/0 mice. 81 Because CDI is not dependent on protease treatment, it allowed us to address fundamental questions concerning the concentration and conformation of different isoforms of sCJD PrP Sc , including protease-sensitive (s) and protease-resistant (r)PrP Sc . 92 The dissociation and unfolding of PrP Sc in the presence of increasing concentration of Gdn HCl can be described as follows: 53, 57, 94 The CDI monitors the global transition from native aggregates to fully denatured monomers of PrP Sc . In contrast, the WB-based techniques monitor either the partial solubilization of PrP Sc 101 or conversion of rPrP Sc to protease-sensitive conformers 72 after exposure to denaturant. As a result, the stability data on soluble Sc conformers in sCJD patients with different wB patterns and PRnP gene polymorphisms. 92 The stability of PrPSc was determined with CDi before and after protease treatment and the change is expressed as ΔGdn HCl 1/2 . 92 The symbols are mean ± SeM in each sCJD group.
jointly represent an important parameter, which is influenced by replication rate, propagation and clearance of prions from the brain. 64, 109 The correlations among the levels of sPrP Sc , the stability of sPrP Sc , and the duration of the disease found in this study all indicate that sPrP Sc conformers play an important role in the pathogenesis. When sPrP Sc is less stable than rPrP Sc , the difference in stability correlates with less accumulated sPrP Sc and shorter duration of the disease. Conversely, when sPrP conformers are more stable than rPrP Sc , we observed the opposite effectmore accumulated sPrP Sc and extended disease duration (Fig. 1) . In laboratory rodent prion models, we found that levels of sPrP Sc varied with the incubation time of the disease 56 and we hypothesized that the molecular mechanism of this link may be related to the replication or clearance rate of prions. 56, 64, 81 Our recent data on sCJD prions extend this observation and indicate that higher levels of less stable sPrP Sc lead to faster progression of the disease. 92 These observations are in accord with the experiments on yeast prions and suggest that the stability of misfolded protein is inversely related to the replication rate. 110 Although the modulating effect of prion clearance in the mammalian brains is likely, 64 the data from both yeast and human prions lead to the hypothesis that the less stable prions replicate faster by exposing more available sites for growth of the aggregates. In mammalian prions, this effect leads to shorter incubation time and faster progression of the disease.
Future Directions
Additional steps are necessary to improve our understanding of the phenotypic diversity of sCJD. One step is to determine whether the mixed WB patterns of Type 1-2 rPrP Sc in the same or different anatomical areas represent a unique conformation or a mixture of conformers, and to map the distribution in the individual brain. 89 Additionally, novel conformational approaches using tandem protein misfolding cyclic amplification (PMCA) and CDI should allow analysis of the impact of different PrP Sc polymorphisms and conformations on the replication rate of human prions. Such studies have clearly broader implications, as recent data suggest that the process of intercellular induction of protein misfolding is relevant in the pathogenesis of growing number of other neurodegenerative diseases.
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The authors thank Pierlugi Gambetti and Witold Surewicz for encouragement and stimulating discussions. This work was supported by grants from NIA (AG-14359), NINDS (NS074317), CDC (UR8/CCU515004) and the Charles S. Britton Fund. 81 Thus, the detection by CDI of sPrP Sc as a disease-specific marker is widely regarded as a more reliable basis for diagnosing prion diseases. This improved detection led to the discovery of a new human prion disorder, variably protease-sensitive prionopathy (VPSPr). 17, 56, 81, 90, 108 It is noteworthy that synthetic prions generated in vitro during polymerization of recombinant mouse PrP into amyloid fibers produced prions composed exclusively of sPrP Sc upon inoculation into wild mice. 106 Our recent data indicate that the levels as well as stability of sPrP Sc are a good predictor of the progression rate in sCJD (Fig. 1) . 92 Despite the inevitable influence of variable genetic background and the potential difficulties in evaluating initial symptoms, the disease progression rate and incubation time
